BCRX
BioCryst Pharmaceuticals, Inc.
8.25
+
0.29
3.64%
1 x 8.21
1 x 8.28
bid
ask
12:18 PM
timesize
Bearish
31
Bullish
78
sentiment
8.02
day range
8.30
4.13
52 week range
8.69
News
...
Profile
...
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | -0.07 | N/A | N/A | N/A |
2024-08-05 | 2024-06 | -0.19 | -0.06 | 0.13 | 68.42% |
2024-05-06 | 2024-03 | -0.23 | -0.17 | 0.06 | 26.09% |
2024-02-26 | 2023-12 | -0.24 | -0.28 | -0.04 | -16.67% |
2023-11-02 | 2023-09 | -0.25 | -0.19 | 0.06 | 24.00% |
2023-08-03 | 2023-06 | -0.25 | -0.24 | 0.01 | 4.00% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-24 | RBC Capital | Upgrade | Outperform | Outperform |
2023-09-17 | RBC Capital | Upgrade | Sector Perform | Outperform |
2023-08-03 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
2023-08-03 | Jefferies | Upgrade | Hold | Buy |
2023-08-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-02 | Needham | Upgrade | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-06-11 | ABERCROMBIE GEORGE B | Director | 36.43K | Stock Award(Grant) |
2024-06-11 | ASELAGE STEPHEN J | Director | 72.66K | Stock Award(Grant) |
2024-06-11 | GALSON STEVEN K | Director | 58.37K | Stock Award(Grant) |
2024-06-13 | HEGGIE THERESA | Director | 52.85K | Sale |
2024-06-11 | HUTSON NANCY J | Director | 93.64K | Stock Award(Grant) |
2024-06-11 | LEVIN ALAN G | Director | 51.77K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 15.50M | 109.09M | 8.18% |
2023-06-29 | Vanguard Group Inc | 15.09M | 106.23M | 7.96% |
2023-06-29 | Baker Brothers Advisors, LLC | 12.71M | 89.48M | 6.71% |
2023-06-29 | State Street Corporation | 12.26M | 86.34M | 6.47% |
2023-06-29 | Avoro Capital Advisors LLC | 12.06M | 84.87M | 6.36% |
2023-06-29 | Assenagon Asset Management S.A. | 5.33M | 37.54M | 2.81% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 8.22M | 58.41M | 4.34% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 5.86M | 41.26M | 3.09% |
2023-08-30 | iShares Russell 2000 ETF | 4.29M | 30.51M | 2.26% |
2023-08-30 | Fidelity Select Portfolios - Biotechnology | 2.81M | 19.96M | 1.48% |
2023-06-29 | Vanguard Extended Market Index Fund | 2.58M | 18.14M | 1.36% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.44M | 17.17M | 1.29% |
Dividend
...
Dividend | Date |
---|---|
0 | 2014-06-11 |
0 | 2014-06-05 |
0 | 2014-05-20 |
0 | 2014-05-16 |
0 | 2014-04-02 |
This topic has been deleted. Only users with topic management privileges can see it.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
The post here showing the study won’t be done until May 2021 is helpful , that’s too long a wait for myself, in the meantime the stock gets manipulated enough to suck you in, then the price is dropped. Been following it for monthes. Sold, saw the brief tease of it going up bought back in too high, got burned again. All the notes of its potential does no good unless real news comes out by the Company. I’ll wait for the next fishing tease and get out once again, not willing to tie up my money for another 10 monthes.
-
-
-
Biocryst Pharmaceuticals Inc. [BCRX] Shares Rise 0.51 % on Wednesday
news.google.com • -
Is Biocryst Pharmaceuticals Inc. (BCRX) a good investment opportunity?
news.google.com • -
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
globenewswire.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript
seekingalpha.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
7 Small-Cap Stocks to Buy for Large-Scale Gains
investorplace.com • -
BioCryst to Report Second Quarter 2024 Financial Results on August 5
globenewswire.com • -
ORLADEYO® (berotralstat) Approved in Peru
globenewswire.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com •